<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579527</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00011583</org_study_id>
    <secondary_id>2R01AI047040-11A2</secondary_id>
    <secondary_id>R56 Bridge R01AI4704011A1</secondary_id>
    <secondary_id>5K12HD043494-09</secondary_id>
    <secondary_id>R01AI047040</secondary_id>
    <secondary_id>R01AI054843</secondary_id>
    <secondary_id>#950</secondary_id>
    <nct_id>NCT00579527</nct_id>
  </id_info>
  <brief_title>Phase I/II Thymus Transplantation With Immunosuppression #950</brief_title>
  <acronym>#950</acronym>
  <official_title>Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M. Louise Markert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enzyvant Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to determine if thymus transplantation with immunosuppression is a safe
      and effective treatment for atypical complete DiGeorge anomaly. This study will also evaluate
      whether thymus and parathyroid transplantation with immunosuppression is a safe and effective
      treatment for atypical complete DiGeorge anomaly and hypoparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complete DiGeorge anomaly is a congenital disorder characterized by athymia. Without
      successful treatment, children remain immunodeficient and usually die by age 2 years. In
      infants with complete DiGeorge anomaly and no T cells, thymus transplantation without
      immunosuppression resulted in diverse T cell development and good T cell function. Some
      infants with no thymus have some T cells that presumably developed extrathymically; these T
      cells can reject a thymus graft. The purpose of this study is to design better
      immunosuppression use for complete DiGeorge anomaly subjects who have some T cells and
      different T cell function levels. This protocol includes 3 immunosuppression regimens to
      allow subjects with different T cell function levels to be suppressed adequately.

      DiGeorge infants who have successful thymus transplants but remain with hypoparathyroidism
      must go to the clinic for frequent calcium levels and to the hospital for calcium infusions;
      these infants are at risk for seizures from low calcium. This study had a parental
      parathyroid transplant arm for subjects with hypoparathyroidism who require calcium
      replacement.

      Whether or not a subject was enrolled in the parathyroid arm, the immunosuppression regimen
      the subject received was dependent on the immune findings as stated in the clinical protocol.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/toxicity of 3 immunosuppression regimens in subjects undergoing thymus transplantation. Assessment will be survival at 1 year; incidence of fatal, severe, moderate, and disseminated infections; and, incidence of Grade 3 and 4 toxicities.</measure>
    <time_frame>1 year post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thymopoiesis: assessment will be done by evaluating thymus graft biopsy tissue post transplantation</measure>
    <time_frame>2 - 3 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of T cell numbers and function post thymus transplantation using the 3 regimens tested.</measure>
    <time_frame>Ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of parental parathyroid transplantation. Number of subjects who are off both calcium and calcitriol supplementation. The time at which calcium supplementation needs to be resumed post parathyroid transplant will also be recorded.</measure>
    <time_frame>1 year post-transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>DiGeorge Anomaly</condition>
  <condition>Complete DiGeorge Anomaly</condition>
  <condition>Complete Atypical DiGeorge Anomaly</condition>
  <condition>Complete DiGeorge Syndrome</condition>
  <condition>Complete Atypical DiGeorge Syndrome</condition>
  <arm_group>
    <arm_group_label>#1 Typ &amp; Atyp cDGA w immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV pre thymus transplantation or pre thymus and parathyroid transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-thymus or pre thymus &amp; parathyroid transplant cyclosporine (Csa) are started as soon as complete DiGeorge anomaly (cDGA) is diagnosed. Csa continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately. Pre-transplant steroids are used is pre-transplant T cells &gt;4,000cumm. Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV are given pre-thymus transplant or thymus &amp; parathroid transplant. Medications (diphenenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-thymus or thymus &amp; parathyroid transplant, cyclosporine (Csa) and steroids are started after complete DiGeorge anomaly (cDGA) is diagnosed. After PHA response is documented &gt;40,000 cpm on suppression, peri-transplant Csa target trough levels are 250-300 ng/ml. (Levels outside of range, dose modified.) If subject cannot tolerate Csa, change to tacrolimus (target trough level 10-15 ng/ml). When trough levels are outside of range, dosing is modified appropriately. Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV are given pre-transplant. Medications (diphenenhydramine, steroids, &amp; acetaminophen) are given with rabbit anti-thymocyte globulin. Daclizimab 1 mg/kg single dose IV and Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV/orally may be given depending on T cell counts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymus Tissue for Transplantation</intervention_name>
    <description>Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and donor's biological mother are screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue if transplanted into the subject's quadriceps. Two to three months post thymus transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.</description>
    <arm_group_label>#1 Typ &amp; Atyp cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>Thymus Tissue Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thymus Tissue and Parental Parathyroid Transplantation</intervention_name>
    <description>If the recipient has hypoparathyroidism, and is eligible, the subject may receive both a thymus and parathyroid transplant. If the subject is not eligible the subject will receive only a thymus transplant. For parathyroid transplant, parental parathyroid donors screened. If both parents met criteria, parathyroid harvested from the parent who shares the most HLA alleles with the thymus donor. Parathyroid harvest is done under general anesthesia. One parathyroid gland is minced and placed in quadriceps muscle of 1 leg; there is no dose. No biopsy is done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.</description>
    <arm_group_label>#1 Typ &amp; Atyp cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <other_name>Thymus and Parathyroid Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab amy be done.</description>
    <arm_group_label>#1 Typ &amp; Atyp cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>Venipuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit anti-thymocyte globulin</intervention_name>
    <description>Three doses of 2 mg/kg IV prior to thymus or thymus and parathyroid transplantation. Each dose is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to thymus or thymus and parathyroid transplantation. Medications (diphenenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.</description>
    <arm_group_label>#1 Typ &amp; Atyp cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>RATGAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation or thymus and parathyroid transplantation. The Csa dose is dependant on T cell numbers and the targert Csa trough levels. Csa is weaned as per protocol.</description>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>Csa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after the thymus transplant or the thymus/parathyroid transplant. FK506 dose is dependent on the T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.</description>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone or Prednisolone</intervention_name>
    <description>Steroids IV or orally may be given before and after thymus or thymus/parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Steroids are weaned as per protocol.</description>
    <arm_group_label>#2 Atypical cDGA w immunosuppression</arm_group_label>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>Steroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab</intervention_name>
    <description>A single dose of Daclizumab 1 mg/kg IV may be given. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Daclizumab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after thymus transplantation.</description>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>Zenapax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after thymus transplantation or continued for up to six months after thymus transplantation.</description>
    <arm_group_label>#3 Atyp cDGA w additional suppression</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Tx Inclusion:

          -  Must have 1 of following: 22q11 or 10p13 hemizygosity; hypocalcemia requiring
             replacement; congenital heart defect; CHARGE association or CHD7 mutation; or abnormal
             ears plus mother w/diabetes (type I, type II, gestational).

          -  &lt;50 CD3+ T cells/cumm or &lt;50 CD3+ T cells/cumm that are CD62L+ CD45RA+, or &lt;5% of CD3+
             count being CD62L + CD45RA+

        Atypical DiGeorge: Must have, or have had, a rash. If rash present, rash biopsy must show T
        cells in skin. If rash &amp; adenopathy resolved, must have &gt;50/cumm T cells &amp; naive T cell
        must be &lt;50/cumm or &lt;5% of T cells.

        Typical DiGeorge: CD3+ CD45RA+ CD62L+ T cells &lt;50/mm3 or &lt;5% of total T cells

        - Must be eligible for 1 of 3 Regimens:

        R#1 - Typical DiGeorge with PHA response &gt;5000 cpm and &gt;20 fold response. Must have PHA
        response &lt;50,000cpm. If PHA response &gt;50,000 pre-tx, subject will move to R#2.

        R#2 - Typical DiGeorge with PHA responses &gt;50,000 cpm; or atypical DiGeorge with PHA
        response &lt;75,000cpm (when not on immunosuppression) or &lt;40,000 cpm to PHA while on
        immunosuppression.

        R#3 - Atypical DiGeorge with PHA responses &gt;75,000cpm while on no immunosuppression or PHA
        responses &gt;40,000cpm while on immunosuppression pre-tx.

        Parathyroid Tx Additional Inclusion:

          -  2 studies which PTH&lt;5 pg/ml when ionized calcium &lt;1.1 mmol/L. Can be done anytime
             pre-tx; 1 must be done while at Duke Hospital.

          -  Parent(s) willing &amp; eligible to be donors

        Tx Exclusion:

          -  Heart surgery &lt;4 wks pre-tx

          -  Heart surgery anticipated w/in 3 months after proposed tx

          -  Rejection by surgeon or anesthesiologist as surgical candidate

          -  Lack of sufficient muscle tissue to accept transplant of 4 grams/m2 BSA

          -  HIV infection

          -  Prior attempts at immune reconstitution, such as bone marrow tx or previous thymus tx

          -  CMV(&gt;500 copies/ml blood by PCR on 2 tests)

          -  Ventilator dependence

        Parathyroid Donor Inclusion:

        •&gt;18 years of age

          -  Serum calcium in normal range

          -  Normal PTH function

          -  HLA typing consistent with parentage

          -  Not on anticoagulation or can come off

          -  Parent chosen will share HLA-DR allele with thymus donor that was not inherited by the
             recipient. If no HLA matching at all, then either parent acceptable if meet other
             criteria.

        Parathyroid Donor Exclusion:

          -  &lt;18 years old

          -  Hypoparathyroidism-low PTH in presence of low serum calcium &amp; high serum phosphate

          -  Hyperparathyroidism(or history)-elevated PTH in presence of high serum calcium and low
             serum phosphate.

          -  History of cancer

          -  Donor only living involved parent/guardian of recipient

          -  Evidence of HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B, hepatitis C, West
             Nile virus, or Chagas disease

          -  Creutzfeldt Jakob disease (CJD)

          -  Elevated liver function studies: AST, ALT, alkaline phosphatase &gt;3x upper normal limit

          -  Receipt of xenograft or risk factors for SARS, CJD and/or smallpox exposure. {If CJD
             risk factors but not active disease, parent may give permission for parathyroid use.}

          -  Urine CMV positive

          -  Positive CMV IgM

          -  Positive IgM anti-EBV VCA

          -  On blood thinners and cannot stop for parathyroid donation

          -  Elevated PT or PTT (&gt;ULN)

          -  Platelets&lt;100,000

          -  Positive Toxoplasma IgM

          -  Donor will receive a history and physical; may be excluded based on PI's medical
             judgment.

          -  Hemoglobin &lt;9g/dl

          -  Infectious head or neck lesion

          -  Goiter on ultrasound

          -  Abnormal fiberoptic laryngoscopy of vocal cords

          -  HLA inconsistent with parentage

          -  Pregnancy

          -  Positive HSV IgG isn't exclusion; post-tx prophylaxis needed for recipient if donor is
             HSV IgG+.

          -  Positive VZV IgG isn't exclusion; post-tx prophylaxis needed if donor is VZV IgG+.

          -  Medical concern of independent otolaryngologist.

          -  Concern by medical psychologist/social worker that potential donor isn't competent or
             does not understand risks.

          -  Questionnaire responses can lead to exclusion.

        Biological Mother Inclusion:

        • Provides consent to use blood/buccal sample. No exclusions except unwillingness to
        consent; or, provide blood/buccal sample.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Louise Markert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Pediatrics, Allergy &amp; Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15;109(10):4539-47. Epub 2007 Feb 6.</citation>
    <PMID>17284531</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sedlak DA, Sempowski GD, Hale LP, Rice HE, Mahaffey SM, Skinner MA. Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. Blood. 2004 Oct 15;104(8):2574-81. Epub 2004 Apr 20.</citation>
    <PMID>15100156</PMID>
  </reference>
  <reference>
    <citation>Markert ML and Devlin BH. Thymic reconstitution (in Rich RR, Shearer WT, Fleischer T, Schroeder HW, Weyand CM, Frew A, eds., Clinical Immunology 3rd edn., Elsevier, Edinburgh) p 1253-1262, 2008.</citation>
  </reference>
  <reference>
    <citation>Selim MA, Markert ML, Burchette JL, Herman CM, Turner JW. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol. 2008 Apr;35(4):380-5. doi: 10.1111/j.1600-0560.2007.00816.x.</citation>
    <PMID>18333898</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Devlin BH, Li YJ, Markert ML. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol. 2008 Mar;126(3):277-81. Epub 2007 Dec 26.</citation>
    <PMID>18155964</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sempowski GD, Rhein ME, Szabolcs P, Hale LP, Buckley RH, Coyne KE, Rice HE, Mahaffey SM, Skinner MA. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol. 2004 Apr;113(4):734-41.</citation>
    <PMID>15100681</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, Le Deist F, Alexieff MJ, Li J, Hauser ER, Haynes BF, Rice HE, Skinner MA, Mahaffey SM, Jaggers J, Stein LD, Mill MR. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003 Aug 1;102(3):1121-30. Epub 2003 Apr 17.</citation>
    <PMID>12702512</PMID>
  </reference>
  <reference>
    <citation>Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol. 2011 Sep;140(3):244-59. doi: 10.1016/j.clim.2011.04.004. Epub 2011 Apr 16.</citation>
    <PMID>21565561</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Olson JA, Skinner MA, McCarthy EA, Gupton SE, Chen DF, Bonilla FA, Roberts RL, Kanariou MG, Devlin BH, Markert ML. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol. 2010 Oct;126(4):814-820.e8. doi: 10.1016/j.jaci.2010.07.016. Epub 2010 Sep 15.</citation>
    <PMID>20832849</PMID>
  </reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol. 2010 May;135(2):236-46. doi: 10.1016/j.clim.2010.02.007. Epub 2010 Mar 16. Review.</citation>
    <PMID>20236866</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Li J, Devlin BH, Hoehner JC, Rice HE, Skinner MA, Li YJ, Hale LP. Use of allograft biopsies to assess thymopoiesis after thymus transplantation. J Immunol. 2008 May 1;180(9):6354-64.</citation>
    <PMID>18424759</PMID>
  </results_reference>
  <results_reference>
    <citation>Hudson LL, Louise Markert M, Devlin BH, Haynes BF, Sempowski GD. Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol. 2007 Oct;19(5):297-309. Epub 2007 Nov 26. Review.</citation>
    <PMID>18035553</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. Epub 2008 Jun 28.</citation>
    <PMID>18557726</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA, Chinn IK, Hale LP. Thymus Transplantation in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Eds Lavinin C, Moran CA, Morandi U, Schoenhuber R. Springer-Verlag Italia, Milan, 2008, pp 255-267.</citation>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. doi: 10.1007/s12026-008-8082-5.</citation>
    <PMID>19066739</PMID>
  </results_reference>
  <results_reference>
    <citation>Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly. Clin Exp Immunol. 2013 Jul;173(1):140-9. doi: 10.1111/cei.12088.</citation>
    <PMID>23607606</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <disposition_first_submitted>December 10, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 15, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 17, 2012</disposition_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>M. Louise Markert</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>DiGeorge Anomaly</keyword>
  <keyword>Thymus Transplantation</keyword>
  <keyword>DiGeorge Syndrome</keyword>
  <keyword>Athymia</keyword>
  <keyword>Parathyroid Transplantation</keyword>
  <keyword>Hypocalcemia</keyword>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>Low T cell numbers</keyword>
  <keyword>Immunoreconstitution</keyword>
  <keyword>Immunodeficiency</keyword>
  <keyword>Complete DiGeorge Anomaly</keyword>
  <keyword>Complete Atypical DiGeorge Anomaly</keyword>
  <keyword>Complete DiGeorge Syndrome</keyword>
  <keyword>Complete Atypical DiGeorge Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>DiGeorge Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

